Connect with us


Tesseract Health Raises $80M in Financing

It’s developing an eye-imaging diagnostic technology platform.




GUILFORD, CT — Tesseract Health Inc. has raised $80 million in financing.

The company will use the funds to advance its Tesseract iC eye-imaging diagnostic technology platform, accelerate the push to obtain U.S. and international regulatory clearances, and ramp up manufacturing. The funds will also be used to further enhance Tesseract’s AI capabilities and prepare the company for commercial launch.

Tesseract’s oversubscribed Series B financing round included support from investors including Foresite Capital, Glenview Capital and Opaleye.

According to the company’s press release:

The Tesseract iC platform (not yet cleared by the US FDA) is intended to diagnose a wide range of diseases without drawing blood. The platform includes a novel chemical sensor and combined, multiple dimensions of imaging technology and AI to image the retina, which is the only part of the human body where it is possible to directly see arteries, veins, capillaries, and nerves. The Tesseract iC platform is a binocular eye imaging device that is portable, affordable, and operable by anyone, supporting a post COVID world focused on cloud-connected telemedicine. Tesseract plans to usher in a new branch of diagnostics fusing the best of imaging and laboratory medicine, a truly world’s first to support screening, diagnosis, monitoring and treatment in a number of clinical domains to go well beyond ophthalmology to primary care, cardiology, neurology and more.

“Our mission is to democratize healthcare on a global scale,” commented company founder, Dr. Jonathan Rothberg. “Tesseract aims to disrupt healthcare by leveraging the wealth of information that exists in the human eye to promote health equity. Everyone, anywhere, must have access to life saving diagnostic information. With Tesseract’s device, we believe they will.”

“We are excited about the potential of the Tesseract iC to combine a portable, non-invasive view of the eye with advances in AI,” said Jim Tananbaum, CEO and Managing Director of Foresite Capital. “We believe this combination will unlock the potential of the human eye to transform diagnostics.” Vik Bajaj, Managing Director at Foresite Capital, will be joining the Tesseract board of directors.

“We are pleased to co-invest with Jonathan and the Tesseract team to advance the development of its innovative retinal imaging platform,” said Larry Robbins, CEO of Glenview Capital. “Our investment directly aligns with our strategy to support affordable, portable and non-invasive diagnostic platforms to monitor and assess patient health across the broadest range of care settings and geographies.” Lee Hathaway, Partner and Co-Head of Healthcare Investing at Glenview, will be joining the Tesseract board of directors.




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular